Golden Meditech Releases FY2008/09 Inter...( Cord Blood Bank Services: Revenue Up...),Health

Cord Blood Bank Services: Revenue Up 77%, and Pending Spin-Off and Listing

on NYSE

Strategic Investment: To Be Listed on NASDAQ

HONG KONG, Nov. 12 /Xinhua-PRNewswire-FirstCall/ -- China's leading integrated medical device and healthcare services provider, Golden Meditech Company Limited ("Golden Meditech" or "the Group", HKEx: 8180) today announced the interim results of financial year 2008/09. During the period under review, the Group has not only sustained high growth of key businesses, but also made significant progress with the proposed overseas listing of the umbilical cord blood bank business and market expansion beyond China.

In the first half of this year, the Group recorded turnover totaling HK$ 241,109,000, a 27% increase on a year on year basis.

Mr. KAM Yuen, Chairman and CEO of Golden Meditech, said that the Group, being a China-focused healthcare company, is benefited from the sustained growth of China's economy and the strong market dynamics of the healthcare industry. In the first six months of this year, revenues of the umbilical cord blood bank services and the ABRS consumables increased by 77% and 36% respectively. The cord blood bank services division has contributed up to 39% of the Group's total revenue, he noted.

He further explained that all the Group's key businesses have great potential to be explored. In domestic market, the Group sustained the high growth of umbilical cord blood bank business and reported over 45% increase of the newly sign-up customers during the period under review. The number of new sign-ups increased remarkably by over 75% in the second quarter on a year-on- year basis.

As part of its efforts to expand overseas, the Group, through CCBS, increased its strategic shareholding of Cordlife (Stock Code: CBB.AX) listed on Australia Stock Exchange and became the latter's single largest shareholder. This makes CCBS not only the largest
'/>"/>